Q1 2022 Results

Company overview Financial review 2022 priorities Appendix References Entresto® +42% cc, growing strongly across geographies Sales evolution USD m, % cc Ex-US US weekly NBRx1 New-to-brand prescriptions (000) US +42% cc 7 1,093 CO 6 8 789 551 5 407 4 542 3 Mm 382 2 Q1 2021 Q1 2022 01/19 04/19 07/19 10/19 01/20 04/20 07/20 10/20 01/21 04/21 NBRX New-to-brand Prescriptions 9 Investor Relations | Q1 2022 Results 07/21 10/21 01/22 04/22 ☐ 1 GROWTH C Entresto AZ K KL Strong quarter performance² ☐ US: growth across hospitals, cardiology and primary care ☐ Europe: strong demand growth China: NRDL-driven growth in HF/HTN Confident in future growth ☐ ☐ Broad evidence across clinical and real- world settings 3,4 Guidelines drive 1st choice in HFrEF5 Opportunity for further penetration in HF and uptake in HTN in China/ Japan² NRDL - National Reimbursement Drug List HF - Heart Failure HTN Hypertension See References at end of this presentation ✓ NOVARTIS | Reimagining Medicine

View entire presentation